

COVANCE LAB SERVICES & LABCORP

Performed **>100 biomarker** studies since 2011, supporting immuno-oncology **drug development**




>55 countries




>3800 sites




>19000 patients



All current **companion/complementary** diagnostics have been **commercialized** through **LabCorp**



>110 immuno-oncology clinical trials



19 indications

COVANCE CLINICAL DEVELOPMENT

Managed **38** immuno-oncology clinical trials in **12 indications** since 2011

14

Phase I Trials



6
NSCLC & SCLC



3
Prostate Cancer



5
Pancreatic Cancer

9

Phase II trials



5
Melanoma




5
Glioblastoma



2
Breast Cancer

15


Phase III trials



A full service partnership with Covance can save up to **56 weeks** across the oncology drug development lifecycle

COVANCE EARLY DEVELOPMENT

Supported **>10** immuno-oncology drug classes




T cell

EGFR
GITR
LAG-3
OX40
CTLA4
TIGIT
TIM-3
TLR9




Immunotherapies

Vaccines
Oncolytic adenoviruses
Autologous cellular immunotherapies



Tumor cell

VISTA
PD-1/PD-1L
IDO
CD40/73



Other targets

CD20
CSF-1R
IFN
IL13/18

>100 cell line models

Lung **17**
Leukemia **13**
Breast **10**
Colon **8**
Lymphoma **6**
Melanoma **5**
Brain **5**

